The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)

Published: 13-Oct-2026
Regulatory

With the right questions and scrutiny during procurement, organisations can avoid the over-engineering trap and select a QMS solution that fits their requirements and allows them to remain competitive

You need to be a subscriber to read this article.
Click here to find out more.
The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)

The bar for what constitutes an “enterprise” regulatory technology platform has crept steadily higher during the past decade.

The cost of complexity: why mid-tier manufacturers need to rethink regulatory technology strategy (part I)

Ten years ago, a quality management system (QMS) with cloud functionality and electronic submissions might have qualified as enterprise.

Today, forward-looking mid-tier manufacturers require a robust electronic QMS and regulatory information management (RIM) solutions with built-in artificial intelligence (AI) capabilities to stay competitive.

What has not changed, and is unlikely to, are the harsh realities of GxP-regulated software ownership and the hidden costs of buying too much technology.

Mike King, Senior Director, Product and Strategy, Quality, Regulatory, Safety and Detect at IQVIA, takes up the story.

Consider a mid-tier pharmaceutical manufacturer that spends more than £500,000 per year on quality and regulatory software only to find that their team regularly uses less than 50% of the functionality they pay for. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • IQVIA
See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Quality management during manufacturing changes: part I

Quality management during manufacturing changes: part I

Read more
Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards

Trending Articles

  1. ASA bans first weight loss pill ads The UK's advertising watchdog has ruled against several companies advertising oral GLP-1 weight loss medications to the UK public, working with the MHRA to ensure compliance and "protect the public"
  2. FDA Form 483 explained: responding to findings and managing regulatory risk Explore what a Form FDA 483 means, how to respond within 15 business days, assess patient risk, address observations and understand how FDA evaluates responses and inspection outcomes
  3. Why staying connected matters for today’s qualified persons Helen explains how the NSF QP Alumni community helps Qualified Persons stay current through regulatory updates, peer discussions and shared experience, offering practical insight into evolving industry challenges
  4. FDA inspection readiness: Preparing for surveillance and pre-approval inspections Preparing pharma and biotech teams for continuous FDA inspection readiness, mock inspections and proactive regulatory risk management
  5. FDA warns Fresenius Kabi over sterile manufacturing violations The agency has cited serious CGMP deficiencies at Fresenius Kabi’s Melrose Park facility, including failures involving aseptic processing, investigations, bioburden controls and visual inspection — even finding hair in some products

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing
Quality management during manufacturing changes: part I

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Regulatory

Merck and Quintiles sign innovative clinical development partnership

Unique strategic collaboration for development and clinical trial execution
Regulatory

Quintiles invests a further US$14m in China

Will also expand lab testing capabilities with SCRC
Regulatory

Quintiles launches Kun Tuo CRO in China

Will develop customised solutions to assist registration of new medicines in China
Regulatory

Quintiles agrees to buy Advion BioServices

Creates a one-source solution for lab testing
Regulatory

Quintiles opens research centre in Hyderabad, India

Further expands global Phase I service
Regulatory

Quintiles, HKPI and Ramco form jv in Egypt

The companies will provide contract sales force and sales promotion outsourcing services in Egypt
Subscribe now